Clinical trials: Circulating Tumor Cell;
Melanoma (Skin), Melanoma, Stage II
Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION
The trial is looking for new and better ways to treat melanoma, an aggressive type of skin cancer. Having surgery to remove the melanoma will cure the majority of patients with early stage disease.
- Trial name
- DETECTION (NCT04901988)
- Testing
- Nivolumab 10 MG/ML
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- The Christie NHS Foundation Trust
Glioblastoma, Glioma
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients.
- Trial name
- AVA-CELL (NCT01836536)
- Testing
- Bevacizumab standard of care
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Center Eugene Marquis
Breast Cancer, Breast Neoplasms
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
The primary aim of the study is to identify genomic markers (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), transcriptomic markers) as biomarkers of response to neoadjuvant chemotherapy (NAC) among patients with…
- Conditions
- Breast Cancer, Breast Neoplasms, Cancer, Breast
- Trial name
- NCT03709134
- Testing
- Genomic Markers (CTC/ctDNA)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy
This is a non-randomized, open-label phase II clinical trial that studies the effect of reduced dose radiation therapy and chemotherapy after surgery in treating patients with human papillomavirus (HPV) caused throat cancer.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
- Trial name
- NCT04920344
- Testing
- Transoral Surgery, External Beam Radiation Therapy, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Rutgers, The State University of New Jersey
Small Cell Lung Cancer Extensive Stage
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and…
- Trial name
- NCT05066945
- Testing
- Observation
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Breast Cancer
HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC
To evaluate the predictive and prognostic value of HER2 expression of circulating tumor cells in HER2-positive advanced breast cancer patients treated with ADC
- Trial name
- NCT05834686
- Testing
- HER2 expression of circulating tumor cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Solid Tumor, Metastatic Cancer
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy.
- Trial name
- NCT02412462
- Testing
- AB-16B5
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Alethia Biotherapeutics
Healthy Volunteers, Breast Cancer, Metastatic
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
The purpose of this clinical study is to demonstrate that the Parsortix™ PC1 system enables the capture and harvest of circulating tumor cells (CTCs) from the peripheral blood of patients with metastatic breast cancer (MBC) and…
- Trial name
- HOMING (NCT03427450)
- Testing
- Blood draw
- Where
- 4 sites in United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Angle plc
Prostate Cancer
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Primary Objective: To assess effectiveness of prophylactic treatment of hematological complications (grade ≥ 3 neutropenia) resulting from cabazitaxel treatment for 21 days after treatment initiation.
- Trial name
- PROSPECTA (NCT01649635)
- Testing
- CABAZITAXEL (XRP6258), Prednisone, Ciprofloxacin
- Where
- 6 sites in Brazil
- Volunteers
- 45 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal…
- Conditions
- Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
- Trial name
- CheckMate 9TN (NCT03770299)
- Testing
- Nivolumab, Vinorelbine, Gemcitabine
- Sponsor
- Bristol-Myers Squibb
Waldenstrom's Disease, Waldenstrom Macroglobulinemia
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
Waldenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood.
- Trial name
- SLP-rares (NCT04893564)
- Testing
- bone marrow sample, blood sample
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Lung Neoplasm
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Create a living biobank of PDOs from Stage I-III lung cancer patients.
- Trial name
- NCT03655015
- Testing
- Lung Tumor Resection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hepatocellular Carcinoma
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Treatment options for advanced HCC remain very limited.
- Trial name
- IMMUNOCELL (NCT05044676)
- Testing
- patients with hepatocellular carcinoma
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumor, Adult, Healthy Donors
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers.
- Conditions
- Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
- Trial name
- NCT00571389
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- BioCytics, Inc.
Hepatocellular Carcinoma, Desflurane Adverse Reaction
Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor
To investigate the effects of perioperative anesthetic drugs propofol and desflurane on circulating tumor nucleic acids (CK7, ELF3, EGFR and EphB4 mRNA) in the blood of patients with liver cancer, so as to provide scientific…
- Conditions
- Hepatocellular Carcinoma, Desflurane Adverse Reaction, Propofol Adverse Reaction, Circulating Tumor Cells
- Trial name
- NCT05502458
- Testing
- Desflurane, Propofol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Melanoma
Analysis of Circulating Exosomes in Melanoma Patients
The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a biomarker of disease progression in melanoma.
- Trial name
- EXOMEL1 (NCT05744076)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Glioblastoma Multiforme, Healthy Volunteers
Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.
- Trial name
- NCT01135875
- Testing
- GBM Patients, Normal Controls
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Florida
Immune Evasion, Tumor, Neoplastic Cells, Circulating
Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin
Local percutaneous thermal ablation is frequently proposed in the management of metastatic diseases. Radiofrequency ablation (RFA) has demonstrated good results when the metastatic disease is limited and slowly evolving.
- Conditions
- Immune Evasion, Tumor, Neoplastic Cells, Circulating, Circulating Tumor Cell, Pulmonary Metastasis
- Trial name
- ARFIM (NCT03960021)
- Testing
- RFA interventions
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Bergonié
Carcinoma, Hepatocellular
HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC
Early stage HCC is treated by curative surgical resection or by local ablation (such as radio-frequency) as the current standard of care.
- Trial name
- NCT03020342
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital